Established in 2020 Wednesday, April 17, 2024


Positive MRI contrast agent coated by bovine serum albumin nanocage shows high biocompatibility
The BSA cage-like nanoreactor and MR images in vivo. Gadolinium based contrast agent (Gd-DTPA), which is commonly used in clinic, may release a small amount of free Gd ions in vivo. Image courtesy: HMFL.



HEFEI.- Recently, a research team led by Prof. WANG Junfeng from the High Magnetic Field Laboratory of the Hefei Institutes of Physical Science, made a progress in the research of biological protein template regulating the growth of nanocrystals and then performed some applications.

Magnetic resonance contrast agent, which is divided into positive (T1) and negative (T2) contrast agent according to the enhancement type, can improve the image resolution of magnetic resonance imaging (MRI) by changing the signal intensity of biological tissue through internal and external relaxation effect and magnetic susceptibility.

Gadolinium based contrast agent (Gd-DTPA), which is commonly used in clinic, may release a small amount of free Gd ions in vivo, resulting in serious toxicities and side effects, while iron oxide nanoparticles with ultra-small size (less than 5 nm) have good biocompatibility and are considered to be an ideal substitute for gadolinium based contrast agents.




However, the current preparation of small-size iron oxide nanoparticles is usually synthesized in organic solvents, and further hydrophilic ligand replacement is therefore needed, which is expensive and environmentally harmful, resulting in increased difficulty and reduced efficiency of synthesis. Scientists are working to exploring iron oxide nanoparticles with good biocompatibility and high T1 contrast effect in a facile and efficient method.

In this study, the researchers successfully synthesized the ultra-small size Fe2O3@BSA nanoparticles (3.5nm) with highly uniformity and monodispersity, which was regulated by the cage-like protein structure self-assembled of bovine serum albumin (BSA).

Compared with the commercially available Gd-DTPA (Magnevist), Fe2O3@BSA nanoparticles have brighter signal and longer angiographic effect, indicating a great potential as a T1 contrast agent in steady-state and high-resolution MRI.

In addition, they found that owing to the BSA coating, the nanoparticles can be metabolized in vivo and excreted through urine, which has good biological safety and great commercial prospects.

This research was supported by grants from the Ministry of Science and Technology of China and the National Natural Science Foundation of China.







Today's News

January 21, 2021

Rocks show Mars once felt like Iceland

50 million-year-old fossil assassin bug has unusually well-preserved genitalia

Inflamed environment is C. diff paradise

Researchers use lasers and molecular tethers to create perfectly patterned platforms for tissue engineering

A little friction goes a long way toward stronger nanotube fibers

Research finds tiny bubbles tell tales of big volcanic eruptions

Tulane researchers identify potential animal model for severe COVID-19 infections

S. Africa virus strain poses 're-infection risk': study

Solar activity reconstructed over a millennium

Research establishes antibiotic potential for cannabis molecule

Penn study shows outcomes of critically Ill COVID patients improved consistently during the pandemic

Turn back time? Study hints at way to halt decline as we age

Gut bacteria help digest dietary fiber, release important antioxidant

Ultrawide bandgap gives material high-power potential

Asian butterfly populations show different mimicry patterns thanks to genetic 'switch'

Pre-historic Europeans used bronze objects as currency: study

Butterflies create jet propulsion with a clap of their wings

Positive MRI contrast agent coated by bovine serum albumin nanocage shows high biocompatibility

Catnip leaves kitties feline groovy, wards off mosquitoes: study



 


Editor & Publisher: Jose Villarreal
Art Director: Juan José Sepúlveda Ramírez



Tell a Friend
Dear User, please complete the form below in order to recommend the ResearchNews newsletter to someone you know.
Please complete all fields marked *.
Sending Mail
Sending Successful